ALGS
Aligos Therapeutics Inc
NASDAQ: ALGS · HEALTHCARE · BIOTECHNOLOGY
$5.99
+0.34% today
Updated 2026-04-30
Market cap
$39.60M
P/E ratio
—
P/S ratio
18.12x
EPS (TTM)
$-2.45
Dividend yield
—
52W range
$4 – $14
Volume
0.2M
Aligos Therapeutics Inc (ALGS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $-10.55M | $4.36M | $13.91M | $15.53M | $3.94M | $2.19M |
| Revenue growth (YoY) | — | — | — | +141.3% | +219.0% | +11.7% | -74.6% | -44.6% |
| Cost of revenue | $1.29M | $2.30M | $3.33M | $104.15M | $3.67M | $3.07M | $2.62M | $930000.00 |
| Gross profit | $-1.29M | $-2.30M | $-10.55M | $4.36M | $13.91M | $15.53M | $3.94M | $1.26M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 57.5% |
| R&D | $10.46M | $44.04M | $79.89M | $104.15M | $85.08M | $73.04M | $70.27M | $69.45M |
| SG&A | $3.21M | $10.01M | $17.94M | $28.53M | $26.41M | $30.62M | $22.83M | $20.72M |
| Operating income | $-13.66M | $-54.04M | $-97.83M | $-128.32M | $-97.58M | $-88.13M | $-89.15M | $-87.98M |
| Operating margin | — | — | 927.5% | -2943.8% | -701.7% | -567.5% | -2259.9% | -4024.9% |
| EBITDA | $-12.37M | $-49.88M | $-94.51M | $-124.54M | $-93.91M | $-85.06M | $-86.53M | $-87.06M |
| EBITDA margin | — | — | 896.0% | -2857.1% | -675.2% | -547.7% | -2193.5% | -3982.4% |
| EBIT | $-13.66M | $-52.18M | $-97.83M | $-128.32M | $-97.58M | $-88.13M | $-89.15M | $-87.98M |
| Interest expense | $0.00 | $1.86M | $10.55M | $132000.00 | $1.64M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-13.93M | $-52.26M | $-108.54M | $-128.33M | $-96.05M | $-87.68M | $-131.21M | $-24.19M |
| Net income growth (YoY) | — | -275.1% | -107.7% | -18.2% | +25.2% | +8.7% | -49.6% | +81.6% |
| Profit margin | — | — | 1029.0% | -2944.1% | -690.6% | -564.6% | -3326.0% | -1106.7% |